Eosinophil activity in infants hospitalized for wheezing and risk of persistent childhood asthma

Mari K Hyvärinen1, Anne Kotaniemi-Syrjänen, Tiina M Reijonen

  • 1Department of Pediatrics, Kuopio University and Kuopio University Hospital, Kuopio, Finland. ylinen@hytti.uku.fi

Insights

Elevated eosinophil markers in infants hospitalized for wheezing can predict persistent childhood asthma. Nasopharyngeal aspirate eosinophil cationic protein (NPA-ECP) emerged as an independent predictor of asthma persistence.

Area of Science:

  • Pediatrics
  • Allergy and Immunology
  • Respiratory Medicine

Background:

  • Eosinophilic inflammation is key in asthma development.
  • Predicting persistent childhood asthma (PCA) after infantile wheezing is crucial for early intervention.

Purpose of the Study:

  • To determine if blood eosinophil count (B-EOS), serum eosinophil cationic protein (S-ECP), or nasopharyngeal aspirate eosinophil cationic protein (NPA-ECP) predict PCA.
  • To identify independent predictors of asthma persistence.

Main Methods:

  • Prospective cohort study of 100 infants hospitalized for wheezing (<24 months).
  • Measured B-EOS, S-ECP, and NPA-ECP on admission.
  • Assessed asthma status at median ages of 4.0, 7.2, and 12.3 years.

Main Results:

  • 25% of children developed PCA.
  • Elevated B-EOS, S-ECP, and NPA-ECP were associated with increased PCA risk (2.9- to 6.7-fold).
  • NPA-ECP was identified as an independent risk factor for PCA (OR 4.09).

Conclusions:

  • Eosinophil activity in infancy predicts the development of childhood asthma.
  • NPA-ECP is a significant independent predictor of persistent asthma at school age.

Related Concept Videos

Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include: